Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

759 - Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer (HGCSG1403 study)


19 Dec 2015


Poster presentation 1


Hideyuki Hayashi


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


H. Hayashi1, S. Yuki2, K. Sawada2, T. Muranaka3, Y. Kawamoto3, H. Nakatsumi3, Y. Komatsu3

Author affiliations

  • 1 Department Of Internal Medicine And Gastroenterology, Abashiri Kosei General Hospital, 093-0096 - Abashiri/JP
  • 2 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP


Abstract 759


A combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) is one of the standard first-line therapy in patients with unresectable pancreatic cancer. However, implanted central venous access port (CV-port) is essential for the treatment with FOLFIRINOX, so the therapy is somewhat less convenient and is often accompanied by CV-port related problems such as infection and thrombosis especially in case of pancreatic cancer. S-1 is an oral fluoropyrimidine derivative shown to be effective for pancreatic cancer in Japan. CV-port free treatment is feasible by replacing intravenous fluorouracil to orally S-1. Here we developed a new combination chemotherapy regimen consisting of oxaliplatin, irinotecan and S-1 (OX-IRIS).

Trial design

This is a dose-escalation phase I study in Japanese patients with unresectable pancreatic cancer using a standard 3 + 3 design followed by expansion cohorts. Key eligibility criteria are as follows: 1) Pathologically diagnosed invasive ductal carcinoma; 2) Unresectable locally advanced, metastatic, or recurrent disease; 3) No prior chemotherapy or radiotherapy for pancreatic cancer; 4) Aged 20 to 75 years old; 5) ECOG PS of 0 or 1. OX-IRIS regimen consists of 28-day cycles with escalated dose of oxaliplatin (50-85 mg/m2 on day 1 and 15), irinotecan (100-180 mg/ m2 on day 1 and 15) and S-1 (80 mg/m2/day on day 1 to 14). The primary end points are assessment of dose limiting toxicities (DLTs) and determination of maximum tolerated dose (MTD) to investigate the recommended dose (RD) in subsequent phase II study. Secondary endpoints are assessment of safety, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Response is evaluated by investigator by RECIST v1.1 every 6 weeks and adverse effect is monitored and graded according to CTCAE v4.0. MTD is evaluated in cycle 1. This study is recruiting in 2 sites in Japan and registered as UMIN0000170002.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings